Research and Training Grants
Research and Training Grants assist early career scientists in pursuing research and training at a European host institution in a country other than their own country of residence (and exceptionally to support research and training projects outside Europe). These grants may be used to contribute to travel, accommodation and subsistence costs of making the visit. Support is limited to a maximum of €4000.
Applicants should be active microbiologists, having obtained their highest degree less than five years prior to the application deadline date or be a PhD student. They should be a member of a FEMS Member Society. You can find a detailed overview of the requirements for this grant in the FEMS Grants Regulations.
Complete applications should be submitted on or before:
- 1 January for projects that will start within a year from the following 1 March
- 1 July for projects that will start within a year from the following 1 September
You can apply for the upcoming round of Research and Training Grants via our Grants Online submission system.
The FEMS Journals Grants will award an additional € 8,000 in funding to support and stimulate the professional development of early career scientists. This additional funding would not have been possible without the 40 FEMS Journals editors who waived their annual remuneration fee for handling journal manuscripts. This additional funding will feed directly into the next round of the FEMS Research and Training Grants and we are grateful to our editors for making this additional funding available. The FEMS Journal Editors will select grantees to be awarded the FEMS Journals Grant from the next round of Research and Training Grant applications.
Antimicrobial resistance (AMR) is a global problem hindering treatment of bacterial infections, rendering many aspects of modern medicine less effective. AMR genes (ARGs) are frequently located on plasmids, which are self-replicating elements of DNA. They are often transmissible between bacteria, and some have spread globally. Novel strategies to combat AMR are needed, and plasmid curing and anti-plasmid approaches could reduce ARG prevalence, and sensitise bacteria to antibiotics. Currently, there is a general lack of in vivo curing options. This review highlights this important shortfall, which if filled could provide a promising mechanism to reduce ARG prevalence in humans and animals. Plasmid curing mechanisms which are not suitable for in vivo use could still prove important for reducing the global burden of AMR, as high levels of ARGs exist in the environment.